What makes TMB an ambivalent biomarker for immunotherapy? A subtle mismatch between the sample-based design of variant callers and real clinical cohort

Tumor mutation burden (TMB) is a widely recognized biomarker for predicting the efficacy of immunotherapy. However, its use still remains highly controversial. In this study, we examine the underlying causes of this controversy based on clinical needs. By tracing the source of the TMB errors and ana...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yuqian Liu, Shenjie Wang, Yixuan Wang, Yifei Li, Xiaoyan Zhu, Xin Lai, Xuanping Zhang, Xuqi Li, Xiao Xiao, Jiayin Wang
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-05-01
Col·lecció:	Frontiers in Immunology
Matèries:	clinical immunology tumor mutation burden categorization thresholds sequencing data analysis bioinformatics tool measurement error
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1151224/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!